sodium 4'-({6-(5-carbamoylpyridin-2-yl)-4-oxospiro[chroman-2,4'-piperidin]-1'-yl}carbonyl)-2,6-diethoxybiphenyl-4-carboxylate | 1203649-31-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: sodium 4'-({6-(5-carbamoylpyridin-2-yl)-4-oxospiro[chroman-2,4'-piperidin]-1'-yl}carbonyl)-2,6-diethoxybiphenyl-4-carboxylate
• 英文别名: Sodium 4'-({6-(5-carbamoylpyridin-2-yl)-4-oxospiro[chroman-2,4'-piperidin]-1'-yl}carbonyl)-2',6'-diethoxybiphenyl-4-carboxylate；sodium;4-[4-[6-(5-carbamoylpyridin-2-yl)-4-oxospiro[3H-chromene-2,4'-piperidine]-1'-carbonyl]-2,6-diethoxyphenyl]benzoate
• CAS: 1203649-31-3
• 化学式: C₃₇H₃₄N₃O₈*Na
• 分子量: 671.682
• InChiKey: VBXGKWSUAXMXTO-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.32
• 重原子数：
  49
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  161
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  sodium 4'-({6-(5-carbamoylpyridin-2-yl)-4-oxospiro[chroman-2,4'-piperidin]-1'-yl}carbonyl)-2,6-diethoxybiphenyl-4-carboxylate 在 盐酸 作用下， 以 水 为溶剂， 反应 0.5h， 以92%的产率得到4'-({6-(5-carbamoylpyridin-2-yl)-4-oxospiro[chroman-2,4'-piperidin]-1'-yl}carbonyl)-2',6'-diethoxybiphenyl-4-carboxylic acid
  参考文献：
  名称：

  [EN] NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS
  [FR] NOUVEAUX ACIDES SPIROCHROMANONE CARBOXYLIQUES

  摘要：

  该发明涉及一种通式（I）的化合物：其中A代表连接基团；Ar1代表由芳香环形成的基团；R1和R2分别独立地代表氢原子、卤素原子、氰基、C2-C6烯基基团、C1-C6烷氧基团、卤代C1-C6烷氧基团、环C3-C6烷氧基团、C2-C7烷酰基团、卤代C2-C7烷酰基团、C2-C7烷氧羰基团、卤代C2-C7烷氧羰基团、环C3-C6烷氧羰基团、芳基烷氧羰基团、氨基甲氧基基团、羧基C2-C6烯基基团，或-Q1-N（Ra）-Q2-Rb基团；C1-C6烷基基团可选地具有取代基；芳基或杂环基团可选地具有取代基；或C1-C6烷基基团或C2-C6烯基基团具有芳基或杂环基团；T和U分别独立地代表氮原子或亚甲基基团；V代表氧原子、硫原子或亚胺基团。该发明的化合物可用作治疗各种与ACC相关疾病的治疗剂。

  公开号：

  WO2010002010A1
• 作为产物：
  描述：

  methyl 4'-({6-(5-carbamoylpyridin-2-yl)-4-oxospiro[chroman-2,4'-piperidin]-1'-yl}carbonyl)-2,6-diethoxybiphenyl-4-carboxylate 在 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 288.0h， 以52.4%的产率得到sodium 4'-({6-(5-carbamoylpyridin-2-yl)-4-oxospiro[chroman-2,4'-piperidin]-1'-yl}carbonyl)-2,6-diethoxybiphenyl-4-carboxylate
  参考文献：
  名称：

  [EN] NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS
  [FR] NOUVEAUX ACIDES SPIROCHROMANONE CARBOXYLIQUES

  摘要：

  该发明涉及一种通式（I）的化合物：其中A代表连接基团；Ar1代表由芳香环形成的基团；R1和R2分别独立地代表氢原子、卤素原子、氰基、C2-C6烯基基团、C1-C6烷氧基团、卤代C1-C6烷氧基团、环C3-C6烷氧基团、C2-C7烷酰基团、卤代C2-C7烷酰基团、C2-C7烷氧羰基团、卤代C2-C7烷氧羰基团、环C3-C6烷氧羰基团、芳基烷氧羰基团、氨基甲氧基基团、羧基C2-C6烯基基团，或-Q1-N（Ra）-Q2-Rb基团；C1-C6烷基基团可选地具有取代基；芳基或杂环基团可选地具有取代基；或C1-C6烷基基团或C2-C6烯基基团具有芳基或杂环基团；T和U分别独立地代表氮原子或亚甲基基团；V代表氧原子、硫原子或亚胺基团。该发明的化合物可用作治疗各种与ACC相关疾病的治疗剂。

  公开号：

  WO2010002010A1

文献信息

• HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  申请人：Isabel Elise

  公开号：US20110301143A1

  公开（公告）日：2011-12-08

  Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R 1 — substituted heteroaryl, R 1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR 5 R 6 , C═CR 5 or CR 13 —CR 5 R 6 , Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

  结构式（I）的杂环化合物，或其药学上可接受的盐，其中W是R1-取代的杂芳基，R1是取代有酯基或羧基的杂芳基环，X-T是N—CR5R6，C═CR5或CR13—CR5R6，Y是键或—C(O)—，a和b代表选自1到4的整数，Ar是可选择取代的苯基或萘基，是硬脂酰辅酶A 9-脱饱和酶（SCD）的抑制剂。这些杂环化合物对于预防和治疗与异常脂质合成和代谢有关的疾病非常有用，包括心血管疾病、动脉粥样硬化、肥胖症、糖尿病、神经系统疾病、代谢综合征、胰岛素抵抗、癌症、肝脂肪变性和非酒精性脂肪肝。
• [EN] SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] AMINOPIPÉRIDINES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE-IV DANS LE CADRE DU TRAITEMENT DU DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011037793A1

  公开（公告）日：2011-03-31

  The present invention is directed to novel substituted aminopiperidines of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-ΪV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式I的新型取代氨基哌啶，它们是二肽基肽酶-IV酶的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病中有用，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
  申请人：Biftu Tesfaye

  公开号：US20100120863A1

  公开（公告）日：2010-05-13

  The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式I的新型取代氨基四氢吡喃衍生物，它们是二肽基肽酶-IV酶的抑制剂，可用于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗二肽基肽酶-IV酶参与的疾病中的用途。
• [EN] AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES<br/>[FR] AMINOTÉTRAHYDROPANES UTILISÉS COMME INHIBITEURS DE LA DIPEPTYL PEPTIDASE-IV POUR TRAITER OU PRÉVENIR LE DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011028455A1

  公开（公告）日：2011-03-10

  The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式I的新型取代氨基四氢吡喃衍生物，它们是二肽基肽酶-IV酶的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病方面具有用途。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• [EN] FUSED AROMATIC PHOSPHONATE DERIVATIVES AS PRECURSORS TO PTP-1B INHIBITORS<br/>[FR] DÉRIVÉS DE PHOSPHONATES AROMATIQUES FUSIONNÉS UTILISÉS COMME PRÉCURSEURS D'INHIBITEURS DE PTP-1B
  申请人：KANEQ PHARMA

  公开号：WO2013155600A1

  公开（公告）日：2013-10-24

  Fused aromatic phosphonates of structural formula I are precursors to inhibitors of protein tyrosine phosphatase-1B (PTP-1B). The compounds of the present invention are therefore useful for the treatment in a mammal of a disorder, condition, or disease responsive to inhibition of protein tyrosine phosphatase-1B, including Type 2 diabetes, insulin resistance, a lipid disorder, obesity, Metabolic Syndrome, and cancer.

  结构式I的融合芳香族膦酸酯是蛋白酪氨酸磷酸酶-1B（PTP-1B）抑制剂的前体。本发明的化合物因此可用于哺乳动物治疗对蛋白酪氨酸磷酸酶-1B抑制有响应的疾病、病症或疾病，包括2型糖尿病、胰岛素抵抗、脂质紊乱、肥胖症、代谢综合征和癌症。